Bioventus Inc. $BVS Stock Holdings Lifted by American Century Companies Inc.

American Century Companies Inc. raised its stake in Bioventus Inc. (NYSE:BVS) by 18.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,044,212 shares of the company’s stock after buying an additional 159,539 shares during the period. American Century Companies Inc. owned approximately 1.27% of Bioventus worth $9,555,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in BVS. Tower Research Capital LLC TRC raised its stake in Bioventus by 106.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after purchasing an additional 1,786 shares during the period. GAMMA Investing LLC increased its stake in shares of Bioventus by 3,228.7% in the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company’s stock worth $53,000 after acquiring an additional 5,618 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Bioventus by 23,761.5% in the first quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company’s stock worth $57,000 after acquiring an additional 6,178 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Bioventus in the fourth quarter worth $111,000. Finally, ProShare Advisors LLC acquired a new position in shares of Bioventus in the fourth quarter worth $113,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Stock Down 2.3%

BVS stock opened at $7.27 on Wednesday. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $14.38. The company has a 50-day moving average of $6.83 and a two-hundred day moving average of $7.74. The stock has a market capitalization of $601.08 million, a price-to-earnings ratio of -11.92 and a beta of 0.83.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BVS. Cantor Fitzgerald began coverage on shares of Bioventus in a report on Monday, July 7th. They issued an “overweight” rating and a $12.00 price objective for the company. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the stock a “buy” rating in a report on Wednesday, May 7th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.75.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.